NCEL - NLS Pharmaceutics Ltd.

2.77
-0.050   -1.805%

Share volume: 7,721
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$2.82
-0.05
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
-2.12%
1 Month
-10.36%
3 Months
-28.42%
6 Months
39.90%
1 Year
62.94%
2 Year
680.28%
Key data
Stock price
$2.77
P/E Ratio 
0.00
DAY RANGE
$2.75 - $2.85
EPS 
N/A
52 WEEK RANGE
$0.74 - $6.48
52 WEEK CHANGE
$62.94
MARKET CAP 
5.319 M
YIELD 
N/A
SHARES OUTSTANDING 
35.672 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
0.88
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$5,636
AVERAGE 30 VOLUME 
$17,479
Company detail
CEO: Alexander Zwyer
Region: US
Website: nlspharma.com
Employees: 6
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

NLS Pharmaceutics AG is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders. Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy. The company was incorporated in 2015 and is based in Zurich, Switzerland.

Recent news